|
US3910907A
(en)
|
1973-07-09 |
1975-10-07 |
Icn Pharmaceuticals |
Pyrazolo(1,5-a)-1,3,5-triazines
|
|
US5356897A
(en)
|
1991-09-09 |
1994-10-18 |
Fujisawa Pharmaceutical Co., Ltd. |
3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
|
|
ATE257703T1
(de)
|
1997-10-27 |
2004-01-15 |
Takeda Chemical Industries Ltd |
1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
|
|
AU3126700A
(en)
|
1998-12-18 |
2000-07-03 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
US6605623B1
(en)
|
1998-12-18 |
2003-08-12 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
CA2347909A1
(en)
|
1998-12-18 |
2000-06-22 |
Joseph B. Santella, Iii |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
ATE302005T1
(de)
|
1998-12-18 |
2005-09-15 |
Bristol Myers Squibb Pharma Co |
N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
|
|
EP1156807A4
(en)
|
1998-12-18 |
2002-04-03 |
Du Pont Pharm Co |
N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
|
|
AU2057200A
(en)
|
1998-12-18 |
2000-07-03 |
Du Pont Pharmaceuticals Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
WO2001010865A1
(en)
|
1999-08-06 |
2001-02-15 |
Takeda Chemical Industries, Ltd. |
p38MAP KINASE INHIBITORS
|
|
EP1268474A2
(en)
|
2000-03-30 |
2003-01-02 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
WO2001098270A2
(en)
|
2000-06-21 |
2001-12-27 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
EP1363881A2
(en)
|
2000-06-21 |
2003-11-26 |
Bristol-Myers Squibb Pharma Company |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
|
EP1354603A1
(en)
|
2000-12-26 |
2003-10-22 |
Takeda Chemical Industries, Ltd. |
Concomitant drugs
|
|
EP1364949A4
(en)
|
2001-02-02 |
2005-11-23 |
Takeda Pharmaceutical |
JNK INHIBITOR
|
|
ATE404568T1
(de)
|
2001-03-14 |
2008-08-15 |
Gruenenthal Gmbh |
Substituierte thiazolopyrimidine als analgetika
|
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
|
KR20030083016A
(ko)
|
2001-03-28 |
2003-10-23 |
브리스톨-마이어스스퀴브컴파니 |
신규 타이로신 카이나제 억제제
|
|
EP1402900A1
(en)
|
2001-06-11 |
2004-03-31 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions
|
|
EP1441732A2
(en)
|
2001-11-08 |
2004-08-04 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole derivative and pharmaceutical use thereof
|
|
KR20040097375A
(ko)
*
|
2002-04-23 |
2004-11-17 |
시오노기 앤드 컴파니, 리미티드 |
피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
|
|
US7312215B2
(en)
|
2003-07-29 |
2007-12-25 |
Bristol-Myers Squibb Company |
Benzimidazole C-2 heterocycles as kinase inhibitors
|
|
JP4638355B2
(ja)
|
2003-12-26 |
2011-02-23 |
協和発酵キリン株式会社 |
チアゾール誘導体
|
|
PL380764A1
(pl)
|
2003-12-31 |
2007-03-19 |
Schering-Plough Ltd. |
Kontrolowanie pasożytów u zwierząt za pomocą stosowania imidazo [1,2-b] pirydazynowych pochodnych
|
|
GB0401336D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
WO2006070943A1
(ja)
|
2004-12-28 |
2006-07-06 |
Takeda Pharmaceutical Company Limited |
縮合イミダゾール化合物およびその用途
|
|
JP2008542323A
(ja)
*
|
2005-06-01 |
2008-11-27 |
ユセベ ファルマ ソシエテ アノニム |
２−オキソ−１−ピロリジン誘導体、その製造方法及びその使用
|
|
BRPI0812504B8
(pt)
*
|
2007-06-21 |
2021-05-25 |
Cara Therapeutics Inc |
composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
|
|
WO2009027733A1
(en)
|
2007-08-24 |
2009-03-05 |
Astrazeneca Ab |
(2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
|
|
US7868001B2
(en)
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
|
WO2009060197A1
(en)
|
2007-11-08 |
2009-05-14 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazopyridazines for use as protein kinase inhibitors
|
|
US20100029657A1
(en)
|
2008-02-29 |
2010-02-04 |
Wyeth |
Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
|
|
EP2103614A1
(en)
|
2008-03-18 |
2009-09-23 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
|
|
WO2010063487A1
(en)
|
2008-12-05 |
2010-06-10 |
Merz Pharma Gmbh & Co. Kgaa |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
EP2402344A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole fused bicyclic compounds
|
|
EP2402343A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole-fused bicyclic compounds
|
|
EP2402345A1
(en)
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazole fused bicyclic compounds
|
|
EP2402337A1
(en)
*
|
2010-06-29 |
2012-01-04 |
Basf Se |
Pyrazolopyridine compounds
|
|
TWI617559B
(zh)
|
2010-12-22 |
2018-03-11 |
江蘇恆瑞醫藥股份有限公司 |
２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
|
|
WO2012100342A1
(en)
*
|
2011-01-27 |
2012-08-02 |
Université de Montréal |
Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
|
|
WO2012113774A1
(en)
|
2011-02-24 |
2012-08-30 |
Nerviano Medical Sciences S.R.L. |
Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
|
|
UA114490C2
(uk)
|
2011-10-06 |
2017-06-26 |
Байєр Інтеллектуал Проперті Гмбх |
Гетероциклілпіри(mі)динілпіразоли як фунгіциди
|
|
AR088082A1
(es)
|
2011-10-13 |
2014-05-07 |
Lilly Co Eli |
Moduladores selectivos del receptor androgeno
|
|
CN104418821A
(zh)
|
2013-08-22 |
2015-03-18 |
四川大学华西医院 |
2,4位取代的5-(3,4,5-三甲氧基苯基)噻唑衍生物及其制备方法和用途
|
|
BR112016016098A2
(pt)
*
|
2014-01-09 |
2017-08-08 |
Intracellular Therapies Inc |
Compostos orgânicos
|
|
CN107257796A
(zh)
*
|
2014-12-02 |
2017-10-17 |
拜耳医药股份有限公司 |
取代的吡唑并[1,5‑a]吡啶和咪唑并[1,2‑a]吡嗪及其用途
|
|
CN107427521B
(zh)
|
2015-03-27 |
2021-08-03 |
达纳-法伯癌症研究所股份有限公司 |
细胞周期蛋白依赖性激酶的抑制剂
|
|
KR20250099459A
(ko)
|
2015-11-03 |
2025-07-01 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 그의 용도
|
|
EP3442980B1
(en)
*
|
2016-04-15 |
2021-06-09 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
|
CN110072865B
(zh)
*
|
2017-02-08 |
2022-02-11 |
中国医药研究开发中心有限公司 |
吡咯并芳杂环类化合物及其制备方法和医药用途
|
|
US10973820B2
(en)
|
2017-12-13 |
2021-04-13 |
Facio Intellectual Property B.V. |
Compounds for treatment of diseases related to DUX4 expression
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
PE20230407A1
(es)
|
2019-11-11 |
2023-03-07 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
|
|
US20240226098A1
(en)
|
2020-02-28 |
2024-07-11 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
US20230167093A1
(en)
|
2020-04-08 |
2023-06-01 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
KR20230004575A
(ko)
|
2020-04-08 |
2023-01-06 |
레믹스 테라퓨틱스 인크. |
스플라이싱을 조절하기 위한 화합물 및 방법
|
|
TWI782504B
(zh)
|
2020-05-08 |
2022-11-01 |
美商美國禮來大藥廠 |
(三氟甲基)嘧啶-2-胺化合物
|
|
GB202011996D0
(en)
|
2020-07-31 |
2020-09-16 |
Adorx Therapeutics Ltd |
Antagonist compounds
|
|
GB202019622D0
(en)
|
2020-12-11 |
2021-01-27 |
Adorx Therapeutics Ltd |
Antagonist compounds
|
|
WO2022130290A1
(en)
|
2020-12-16 |
2022-06-23 |
New Frontier Labs, Llc |
Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase d toxin
|
|
US11845760B2
(en)
|
2020-12-16 |
2023-12-19 |
Amgen Inc. |
PRMT5 inhibitors
|
|
MX2023006728A
(es)
|
2020-12-16 |
2023-06-19 |
New Frontier Labs Llc |
Esteres de acido dicarboxilico para inducir un efecto analgesico.
|